Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Nov;184(2):559-565.
doi: 10.1007/s10549-020-05867-0. Epub 2020 Aug 17.

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

Shayma Kazmi  1 , Debanjana Chatterjee  2 , Dheeraj Raju  3 , Rob Hauser  3 , Peter A Kaufman  4
Affiliations
Observational Study

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

Shayma Kazmi et al. Breast Cancer Res Treat. 2020 Nov.

Erratum in

Abstract

Purpose: The purpose of this study was to estimate the overall survival (OS) in real-world clinical practice in patients with metastatic breast cancer (MBC) and visceral metastases (liver or lung) treated in the third-line setting with eribulin, gemcitabine or capecitabine overall and in the major clinical categories of MBC (TNBC, HR+/HER2-, and HER2+).

Methods: A retrospective, observational study was conducted with de-identified patient electronic health records from the Cancer Treatment Centers of America (CTCA). Patients with a diagnosis of metastatic breast with lung or liver metastases, and treated with eribulin, gemcitabine, or capecitabine as third-line therapy were included in the analysis. Landmark survival was calculated as percentage of patients alive at 6, 12, 24, and 36 months. Overall survival was compared between treatment arms within TNBC and HR+/HER2- using log-rank analysis. Cox regression analyses was performed to estimate hazard ratios for comparison of treatments within TNBC and HR+/HER2- subtype.

Results: 443 patients with liver or lung metastases received third-line therapy with eribulin (n = 229), gemcitabine (n = 134), or capecitabine (n = 80). Eribulin patients had a higher percentage of patients alive at all landmark timepoints vs. gemcitabine, and a higher percentage of patients alive until 36 months vs. capecitabine. Median survival times showed that overall, and within the TNBC and HR+/HER2- subtype, patients receiving eribulin had a numerically higher median overall survival.

Conclusions: This real-world evidence study is consistent with randomized clinical trial data and demonstrates consistency of eribulin effectiveness in MBC patients with lung or liver metastases overall and in TNBC and HR+/HER2- disease.

Keywords: Eribulin; Metastatic breast cancer; Overall survival; Real-world evidence; Visceral metastases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival Kaplan–Meier graph (eribulin vs gemcitabine and eribulin vs capecitabine) in metastatic triple-negative breast cancer (TNBC) patients
Fig. 2
Fig. 2
Overall survival Kaplan–Meier graph (eribulin vs gemcitabine and eribulin vs capecitabine) in metastatic HR+/HER2− patients
See this image and copyright information in PMC

References

    1. National Cancer Institute (2019) Cancer stat facts: female breast cancer. Surveillance E, and End Results Program. https://seer.cancer.gov/statfacts/html/breast.html. Accessed 10 Sept 2019
    1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29. doi: 10.1634/theoncologist.10-90003-20. - DOI - PubMed
    1. Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2(4):62. doi: 10.1093/jncics/pky062. - DOI - PMC - PubMed
    1. Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150(3):547–557. doi: 10.1007/s10549-015-3352-0. - DOI - PMC - PubMed
    1. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–287. doi: 10.1007/s10549-016-4059-6. - DOI - PubMed

Publication types